色素-话题@MedSci

#色素#

654篇内容 | 6174人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1680769, encodeId=4a1d1680e69a8, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=N Engl J Med 2021：转移性葡萄膜黑色素瘤患者接受tebentafusp治疗的总生存获益, objectType=article, longId=219361, objectId=8ba3219361e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ba3219361e1, replyNumber=0, likeNumber=96, createdTime=2022-03-05, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ba3219361e1, moduleTitle=N Engl J Med 2021：转移性葡萄膜黑色素瘤患者接受tebentafusp治疗的总生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ba3219361e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680764, encodeId=b50e1680e6447, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Eur J Cancer：抗PD-1辅助治疗黑色素瘤的真实临床实践数据！, objectType=article, longId=218204, objectId=bc3421820469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc3421820469, replyNumber=0, likeNumber=72, createdTime=2022-03-01, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc3421820469, moduleTitle=Eur J Cancer：抗PD-1辅助治疗黑色素瘤的真实临床实践数据！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc3421820469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680797, encodeId=a8e41680e970c, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=NKTR-214联合Opdivo治疗黑色素瘤的两项III期研究，结果失败（PIVOT IO-001）, objectType=article, longId=302278, objectId=941a3022e85a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=941a3022e85a, replyNumber=0, likeNumber=98, createdTime=2023-02-01, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=941a3022e85a, moduleTitle=NKTR-214联合Opdivo治疗黑色素瘤的两项III期研究，结果失败（PIVOT IO-001）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=941a3022e85a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680789, encodeId=5f821680e89a6, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Movement disorders：新方法：神经黑色素方法可追踪帕金森病黑色素沉积, objectType=article, longId=300204, objectId=ddef300204b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddef300204b4, replyNumber=0, likeNumber=89, createdTime=2023-01-10, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddef300204b4, moduleTitle=Movement disorders：新方法：神经黑色素方法可追踪帕金森病黑色素沉积, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddef300204b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680812, encodeId=1c0d1680812da, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=J Clin Oncol：I-II期黑色素瘤可能也需要进行辅助治疗, objectType=article, longId=729996, objectId=7189e2999604, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7189e2999604, replyNumber=0, likeNumber=78, createdTime=2023-05-23, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7189e2999604, moduleTitle=J Clin Oncol：I-II期黑色素瘤可能也需要进行辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7189e2999604)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680798, encodeId=8dc91680e982f, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=JAMA Dermatol：全球2020年皮肤黑色素瘤的发病率和死亡率, objectType=article, longId=302298, objectId=64843022983a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64843022983a, replyNumber=0, likeNumber=83, createdTime=2022-10-07, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64843022983a, moduleTitle=JAMA Dermatol：全球2020年皮肤黑色素瘤的发病率和死亡率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64843022983a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680818, encodeId=cd541680818b6, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=J Clin Oncol：Encorafenib联合Binimetinib治疗BRAF V600突变型黑色素瘤的长期效益, objectType=article, longId=734132, objectId=690de34132b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=690de34132b5, replyNumber=0, likeNumber=77, createdTime=2022-12-30, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=690de34132b5, moduleTitle=J Clin Oncol：Encorafenib联合Binimetinib治疗BRAF V600突变型黑色素瘤的长期效益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=690de34132b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680783, encodeId=86361680e83ef, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效, objectType=article, longId=294057, objectId=20b829405e40, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20b829405e40, replyNumber=0, likeNumber=79, createdTime=2022-02-02, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20b829405e40, moduleTitle=J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20b829405e40)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680770, encodeId=c23b1680e701b, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Eur J Cancer：90%以上的皮肤黑色素瘤可归因于太阳紫外线照射？！！, objectType=article, longId=220036, objectId=f15222003699, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f15222003699, replyNumber=0, likeNumber=56, createdTime=2022-02-15, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f15222003699, moduleTitle=Eur J Cancer：90%以上的皮肤黑色素瘤可归因于太阳紫外线照射？！！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f15222003699)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680767, encodeId=eb2b1680e6720, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Int J Epidemiol：常见的遗传多态性会增加慢性淋巴细胞白血病和非黑色素瘤皮肤癌之间的联系, objectType=article, longId=218829, objectId=acda21882903, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=acda21882903, replyNumber=0, likeNumber=73, createdTime=2022-07-10, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=acda21882903, moduleTitle=Int J Epidemiol：常见的遗传多态性会增加慢性淋巴细胞白血病和非黑色素瘤皮肤癌之间的联系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=acda21882903)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680793, encodeId=4f141680e93ed, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Br J Dermatol：我们需要重新考虑对原位黑色素瘤和严重发育异常痣的诊断吗？, objectType=article, longId=300816, objectId=b86130081684, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b86130081684, replyNumber=0, likeNumber=98, createdTime=2022-09-12, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b86130081684, moduleTitle=Br J Dermatol：我们需要重新考虑对原位黑色素瘤和严重发育异常痣的诊断吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b86130081684)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680771, encodeId=f1451680e7150, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=NEJM：转移性葡萄膜黑色素瘤采用Tebentafusp治疗的总生存获益, objectType=article, longId=220044, objectId=e7ea220044a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7ea220044a6, replyNumber=0, likeNumber=68, createdTime=2021-11-12, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7ea220044a6, moduleTitle=NEJM：转移性葡萄膜黑色素瘤采用Tebentafusp治疗的总生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7ea220044a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680747, encodeId=01241680e47f0, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=JNCCN:黑色素瘤患者出现肾上腺转移则对免疫检查点抑制剂耐药, objectType=article, longId=215390, objectId=5ac7215390be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ac7215390be, replyNumber=0, likeNumber=74, createdTime=2022-06-05, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ac7215390be, moduleTitle=JNCCN:黑色素瘤患者出现肾上腺转移则对免疫检查点抑制剂耐药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ac7215390be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680776, encodeId=362a1680e7619, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=eLife：小黑痣是怎么癌变成黑色素瘤的？与周围皮肤中的环境信号有关反应，提高移植细胞的生存率, objectType=article, longId=221202, objectId=9a872212023e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a872212023e, replyNumber=0, likeNumber=101, createdTime=2022-05-21, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a872212023e, moduleTitle=eLife：小黑痣是怎么癌变成黑色素瘤的？与周围皮肤中的环境信号有关反应，提高移植细胞的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a872212023e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680779, encodeId=500c1680e7920, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=J Clin Invest：点阵激光换肤治疗可有效降低衰老皮肤非黑色素瘤皮肤癌的发病风险, objectType=article, longId=221745, objectId=4fd3221e4539, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4fd3221e4539, replyNumber=0, likeNumber=140, createdTime=2022-04-27, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4fd3221e4539, moduleTitle=J Clin Invest：点阵激光换肤治疗可有效降低衰老皮肤非黑色素瘤皮肤癌的发病风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4fd3221e4539)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680795, encodeId=8d8c1680e9580, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=FDA批准LAG-3抗体Relatlimab联合Nivolumab用于不可切除或转移性黑色素瘤的儿童和成人患者, objectType=article, longId=301197, objectId=1dfe30119ee0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1dfe30119ee0, replyNumber=0, likeNumber=76, createdTime=2022-12-24, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1dfe30119ee0, moduleTitle=FDA批准LAG-3抗体Relatlimab联合Nivolumab用于不可切除或转移性黑色素瘤的儿童和成人患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1dfe30119ee0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680775, encodeId=43fc1680e7528, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=J Clin Oncol：纳武单抗联合伊匹单抗治疗晚期黑色素瘤, objectType=article, longId=221149, objectId=c9542211494e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9542211494e, replyNumber=0, likeNumber=78, createdTime=2022-09-26, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9542211494e, moduleTitle=J Clin Oncol：纳武单抗联合伊匹单抗治疗晚期黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c9542211494e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680761, encodeId=bd971680e61f9, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=NEJM：Tebentafusp治疗可改善转移性葡萄膜黑色素瘤患者总生存期, objectType=article, longId=217618, objectId=b49321e61895, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b49321e61895, replyNumber=0, likeNumber=77, createdTime=2022-01-29, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b49321e61895, moduleTitle=NEJM：Tebentafusp治疗可改善转移性葡萄膜黑色素瘤患者总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b49321e61895)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680758, encodeId=d3441680e5888, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Clin Cancer Res：标准剂量的派姆单抗联合不同剂量的伊匹单抗治疗晚期黑色素瘤的疗效和安全性, objectType=article, longId=217050, objectId=249821e0501a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=249821e0501a, replyNumber=0, likeNumber=75, createdTime=2022-08-27, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=249821e0501a, moduleTitle=Clin Cancer Res：标准剂量的派姆单抗联合不同剂量的伊匹单抗治疗晚期黑色素瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=249821e0501a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680784, encodeId=52961680e848a, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Ann Oncol：Ceralasertib (AZD6738)联合durvalumab（德瓦鲁单抗）治疗抗PD-1失败晚期/转移性黑色素瘤患者的疗效, objectType=article, longId=295681, objectId=0b9e295681bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b9e295681bd, replyNumber=0, likeNumber=61, createdTime=2022-12-02, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b9e295681bd, moduleTitle=Ann Oncol：Ceralasertib (AZD6738)联合durvalumab（德瓦鲁单抗）治疗抗PD-1失败晚期/转移性黑色素瘤患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b9e295681bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

色素

2020-05-29

sunylz (审核中...)

前往app查看评论内容

#色素#

N Engl J Med 2021：转移性葡萄膜黑色素瘤患者接受tebentafusp治疗的总生存获益

2022-03-05

sunylz (审核中...)

前往app查看评论内容

#色素#

Eur J Cancer：抗PD-1辅助治疗黑色素瘤的真实临床实践数据！

2022-03-01

sunylz (审核中...)

前往app查看评论内容

#色素#

NKTR-214联合Opdivo治疗黑色素瘤的两项III期研究，结果失败（PIVOT IO-001）

2023-02-01

sunylz (审核中...)

前往app查看评论内容

#色素#

Movement disorders：新方法：神经黑色素方法可追踪帕金森病黑色素沉积

2023-01-10

仁心济世 (审核中...)

前往app查看评论内容

#色素#

J Clin Oncol：I-II期黑色素瘤可能也需要进行辅助治疗

2023-05-23

sunylz (审核中...)

前往app查看评论内容

#色素#

JAMA Dermatol：全球2020年皮肤黑色素瘤的发病率和死亡率

2022-10-07

sunylz (审核中...)

前往app查看评论内容

#色素#

J Clin Oncol：Encorafenib联合Binimetinib治疗BRAF V600突变型黑色素瘤的长期效益

2022-12-30

sunylz (审核中...)

前往app查看评论内容

#色素#

J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效

2022-02-02

sunylz (审核中...)

前往app查看评论内容

#色素#

Eur J Cancer：90%以上的皮肤黑色素瘤可归因于太阳紫外线照射？！！

2022-02-15

sunylz (审核中...)

前往app查看评论内容

#色素#

Int J Epidemiol：常见的遗传多态性会增加慢性淋巴细胞白血病和非黑色素瘤皮肤癌之间的联系

2022-07-10

sunylz (审核中...)

前往app查看评论内容

#色素#

Br J Dermatol：我们需要重新考虑对原位黑色素瘤和严重发育异常痣的诊断吗？

2022-09-12

sunylz (审核中...)

前往app查看评论内容

#色素#

NEJM：转移性葡萄膜黑色素瘤采用Tebentafusp治疗的总生存获益

2021-11-12

sunylz (审核中...)

前往app查看评论内容

#色素#

JNCCN:黑色素瘤患者出现肾上腺转移则对免疫检查点抑制剂耐药

2022-06-05

sunylz (审核中...)

前往app查看评论内容

#色素#

eLife：小黑痣是怎么癌变成黑色素瘤的？与周围皮肤中的环境信号有关反应，提高移植细胞的生存率

2022-05-21

sunylz (审核中...)

前往app查看评论内容

#色素#

J Clin Invest：点阵激光换肤治疗可有效降低衰老皮肤非黑色素瘤皮肤癌的发病风险

2022-04-27

sunylz (审核中...)

前往app查看评论内容

#色素#

FDA批准LAG-3抗体Relatlimab联合Nivolumab用于不可切除或转移性黑色素瘤的儿童和成人患者

2022-12-24

sunylz (审核中...)

前往app查看评论内容

#色素#

J Clin Oncol：纳武单抗联合伊匹单抗治疗晚期黑色素瘤

2022-09-26

sunylz (审核中...)

前往app查看评论内容

#色素#

NEJM：Tebentafusp治疗可改善转移性葡萄膜黑色素瘤患者总生存期

2022-01-29

sunylz (审核中...)

前往app查看评论内容

#色素#

Clin Cancer Res：标准剂量的派姆单抗联合不同剂量的伊匹单抗治疗晚期黑色素瘤的疗效和安全性

2022-08-27

sunylz (审核中...)

前往app查看评论内容

#色素#

Ann Oncol：Ceralasertib (AZD6738)联合durvalumab（德瓦鲁单抗）治疗抗PD-1失败晚期/转移性黑色素瘤患者的疗效

2022-12-02

科室
- - 订阅+
  - 更多科室
工具
服务